Multiple cardiovascular and inflammatory pathway targets

The term "Multiple cardiovascular and inflammatory pathway targets" is a broad, non-canonical grouping which refers to the many molecular entities and signaling pathways implicated in both cardiovascular diseases (such as coronary artery disease, atherosclerosis, myocardial infarction) and inflammatory disorders[1][3][5]. Targets within this group may include cytokines (e.g., interleukin-1β, interleukin-6), enzymes (e.g., p38 MAPK), inflammasome components (e.g., NLRP3), immune receptors (e.g., toll-like receptors, P2X7 receptor), and others. Each of these has unique molecular and functional characteristics, associated biomarkers, interacting drugs, mechanisms of action, and safety considerations[1][3][5]. Therefore, to get structured, actionable information on a therapeutic target, a specific molecule or pathway must be named, such as "NLRP3 inflammasome" or "Interleukin-6 receptor"[1][3][5]. This entry should be flagged as non-specific and not a canonical therapeutic target, as it is a high-level summary rather than an individual molecule[3][5].